PDS Biotechnology Corp director John Andrew Dawson received 22,700 stock options to buy common stock on October 18, 2026, at an exercise price of $1.13 per share. The options vest in three equal annual installments beginning on the first anniversary of the grant, subject to his continued service. His reported resulting position was 22,700 options.
PDS Biotechnology Corp director Deborah Ramsdell received a grant of stock options covering 22,700 shares of common stock on October 18, 2026. The options carry an exercise price of $1.13 per share and expire October 18, 2036. This is an option award, not a reported acquisition of common shares.
PDS Biotechnology Corp director Bruce Wendel received a grant of stock options to buy 22,700 shares of common stock at an exercise price of $1.13 per share. The options vest in three equal annual installments beginning on the first anniversary of the October 18, 2026 grant date, subject to his continued service as a director through each vesting date, and expire October 18, 2036.
PDS Biotechnology Corp (PDSB) lists Deborah Ramsdell as a director in a Form 3 ownership filing.
PDS Biotechnology Corp updated its corporate presentation with clinical-development information on PDS0301 and PDS0101. In an NCI-led, nonrandomized Phase 2 study of PDS0301 plus chemotherapy for MSS/pMMR metastatic colorectal cancer with liver metastases, the reported objective response rate was 71.4% at six months; preliminary results showed approximately 80% survival at 24 months. The PDS0301 results were not from a randomized head-to-head comparison. More than 380 patients have been dosed with PDS0301 across Phase 1 and Phase 2.
In the single-arm VERSATILE-002 study, PDS0101 plus pembrolizumab had median overall survival of 39.3 months in first-line HPV16-positive recurrent/metastatic head and neck cancer. Five PDS0301 readouts are anticipated from Q4 2026 through Q2 2028. A registrational Phase 3 protocol is in design; September 2026 financing proceeds are intended to advance PDS0301 into late-stage clinical development, with an additional tranche committed upon protocol submission to FDA. PDS Biotechnology is seeking a strategic partnership or external funding for further PDS0101 development.
PDS Biotechnology Corporation (PDSB) reports that Kamil Ali-Jackson, Stephen Glover, Gregory Freitag and Otis Brawley resigned from its Board and their committees effective October 18, 2026; Deborah A. Ramsdell, John A. Dawson CBE and Bruce Wendel were appointed effective immediately to fill three of the four vacancies. The Board set its authorized size at seven directors and determined that each non-management director, including the new directors, is independent under applicable Nasdaq listing standards. The resignations were not the result of disagreements with the company.
Each new director received a nonqualified stock option to purchase 22,700 common shares, with an exercise price equal to the common stock’s closing sale price on October 16, 2026, as reported on The Nasdaq Capital Market. The options vest in three annual installments of 7,566, 7,567 and 7,567 shares, subject to continued service through each vesting date.
PDS Biotechnology Corporation (PDSB) is registering for resale by selling stockholders up to 110,001,540 shares of common stock: 16,502,870 issued shares, up to 73,498,156 shares issuable under pre-funded warrants, including up to 50,000,000 tied to the Milestone Closing, and up to 20,000,514 shares issuable under common warrants. Selling stockholders may sell all, some or none, and may not sell under this prospectus until the registration statement is effective. PDSB receives no proceeds from resales; it may receive cash-exercise proceeds at $0.00033 per pre-funded warrant share and $0.22 per common warrant share, intended for working capital and general corporate purposes.
Common shares outstanding were 105,005,429 as of October 9, 2026. The pre-funded and common warrants have beneficial ownership limitations of 19.99% and 19.9%, respectively. Upon submission to the FDA of a registrational Phase 3 clinical trial protocol for PDS0301, Nant and AB Group Ltd. are obligated, subject to applicable closing conditions, to purchase additional securities for $10,000,000 and $1,000,000, respectively.
PDS Biotechnology Corporation will host a virtual key opinion leader event on October 15, 2026, at 8:00 AM, featuring Jonathan M. Hernandez, M.D., an investigator with the Surgical Oncology Program at the National Cancer Institute’s Center for Cancer Research. He will join company management to discuss clinical outcomes from the PDS0301 Phase 2 trials, focusing on metastatic colorectal cancer.
The event will cover the trial in patients with second- and third-line unresectable microsatellite-stable or mismatch repair-proficient colorectal liver metastases. PDS0301 is an investigational IL-12 immunocytokine designed to target tumors and deliver IL-12, with the stated aim of promoting T-cell and natural-killer-cell infiltration and localized anti-tumor activation.